FI48735C - Förfarande för framställning av terapeutiskt värdefulla 3,5-dioxo-1,2- difenyl-4-n-butyl-pyrazolidinderivat. - Google Patents

Förfarande för framställning av terapeutiskt värdefulla 3,5-dioxo-1,2- difenyl-4-n-butyl-pyrazolidinderivat.

Info

Publication number
FI48735C
FI48735C FI673487A FI348767A FI48735C FI 48735 C FI48735 C FI 48735C FI 673487 A FI673487 A FI 673487A FI 348767 A FI348767 A FI 348767A FI 48735 C FI48735 C FI 48735C
Authority
FI
Finland
Prior art keywords
dioxo
diphenyl
butyl
preparation
therapeutically valuable
Prior art date
Application number
FI673487A
Other languages
English (en)
Finnish (fi)
Other versions
FI48735B (sv
Inventor
Negrevergne
Original Assignee
Purdue Frederick Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Frederick Co filed Critical Purdue Frederick Co
Publication of FI48735B publication Critical patent/FI48735B/fi
Application granted granted Critical
Publication of FI48735C publication Critical patent/FI48735C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Drying Of Solid Materials (AREA)
FI673487A 1961-04-24 1967-12-29 Förfarande för framställning av terapeutiskt värdefulla 3,5-dioxo-1,2- difenyl-4-n-butyl-pyrazolidinderivat. FI48735C (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12179661A 1961-04-24 1961-04-24

Publications (2)

Publication Number Publication Date
FI48735B FI48735B (sv) 1974-09-02
FI48735C true FI48735C (sv) 1974-12-10

Family

ID=22398845

Family Applications (2)

Application Number Title Priority Date Filing Date
FI0815/62A FI43993B (sv) 1961-04-24 1962-04-24
FI673487A FI48735C (sv) 1961-04-24 1967-12-29 Förfarande för framställning av terapeutiskt värdefulla 3,5-dioxo-1,2- difenyl-4-n-butyl-pyrazolidinderivat.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI0815/62A FI43993B (sv) 1961-04-24 1962-04-24

Country Status (6)

Country Link
BR (1) BR6238369D0 (sv)
DE (1) DE1470148A1 (sv)
DK (1) DK101791C (sv)
FI (2) FI43993B (sv)
GB (1) GB1002649A (sv)
NO (1) NO117481B (sv)

Also Published As

Publication number Publication date
DE1470148A1 (de) 1969-06-04
BR6238369D0 (pt) 1973-05-10
DK101791C (da) 1965-05-31
FI48735B (sv) 1974-09-02
NO117481B (sv) 1969-08-18
GB1002649A (en) 1965-08-25
FI43993B (sv) 1971-04-30

Similar Documents

Publication Publication Date Title
FI47364C (sv) Förfarande för framställning av terapeutiskt värdefulla 3-indolyl-alif atiskt-syra-föreningar.
BE631848A (fr) Procédé de préparation de trans-diméthylolcyclohexane-1,4.
FI45970C (sv) Förfarande för framställning av terapeutiskt värdefulla 1-substituerad -2-aryl-4- eller 5-nitroimidazoler.
FI49716C (sv) Förfarande för framställning av 2,4-diamino-5-bensyl-pyrimidiner.
FI45557C (sv) Förfarande för framställning av terapeutiskt värdefulla 1,2,4-oxadiazo lderivat.
FI46166C (sv) Förfarande för framställning av tekniskt användbara 2,4,6,8,9-penta-az a-bicyklo/3.3.1/-nona-2,6-diener.
FI46848C (sv) Förfarande för framställning av terapeutiskt verksamma 3-halogen-3H-1, 2-dihydro-1,4-bensodiazepin-2-oner.
FI45180C (sv) Förfarande för framställning av terapeutiskt värdefulla sulfonanilider .
FI49517C (sv) Förfarande för framställning av terapeutiskt värdefull 2'beta-isopropy l-5'alfa-n-propyl-9,10-dihydro-ergopeptin.
FI44622C (sv) Förfarande för framställning av terapeutiskt värdefulla substituerade naftalenderivat.
FI46507C (sv) Förfarande för framställning av en ny terapeutiskt användbar 1-metyl-N -karbo-bensoxi-dihydrolysergamin.
FI47577C (sv) Förfarande för framställning av 2,4,7-triamino-6-fenyl-pteridiner.
DK108971C (da) Fremgangsmåde til fremstilling af 6,17α -dimethylprogesteronderivater.
FI46385C (sv) Förfarande för framställning av 1,3-dihydro-3-hydroxi-2H-1,4-bensodiaz epin-2-onderivat.
FI45043C (sv) Förfarande för framställning av terapeutiskt verksamma, substituerade butynylsuccinimider och -glutarimider.
FI48735C (sv) Förfarande för framställning av terapeutiskt värdefulla 3,5-dioxo-1,2- difenyl-4-n-butyl-pyrazolidinderivat.
FI47358C (sv) Förfarande för framställning av terapeutiskt användbart 4'-demetyl-epi podofyllotoxin-beta-D-glukosid.
FI46621C (sv) Förfarande för framställning av terapeutiskt verkande 5-fenyl-3H-1,4-b ensodiazepinderivat.
FI48732C (sv) Förfarande för framställning av farmakologiskt aktiva 3-substituerad-a mino-1,2,3,4-tetrahydrokarbazoler.
FI52581C (sv) Förfarande för framställning av terapeutiskt användbara N-(1,1-ditieny l-propyl-(3))-fenyletylaminer.
FI46387C (sv) Förfarande för framställning av 2,3,5-tri-O-acetyl-6-azauridin.
FI36690A (fi) Förfarande för framställning av 1,1-dialkylcyklohexantrionderivat
CA613848A (en) Process for the production of cyclododecatri-(1,5,9)-enes
FI45046C (sv) Förfarande för framställning av som lugnande medel verkande 3,8-diazab icyklooktanderivat av fentiaziner.
FI45755C (sv) Förfarande för framställning av 1,2-epoxi-9beta,10alfa-steroider.